Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 10, 2004. The report is a notification of a change in director interests rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of £11.64 per Ordinary Share on June 9, 2004.
Material Changes
The material change reported is the acquisition of Ordinary Shares by Director Mr. J D Coombe under the Company's ShareReward Plan. This transaction involved:
- Acquisition of 11 Ordinary Shares via the partnership element (personal contribution).
- Acquisition of 11 Ordinary Shares via the matching element (Company contribution).
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. It is strictly a disclosure of director shareholding changes.
Investor Verification Points
- Verify the total shareholding of Mr. J D Coombe following this transaction.
- Confirm the terms of the ShareReward Plan entered into on October 5, 2001.
- Review the full annual report (Form 20-F) for comprehensive financial performance data, as this filing does not include it.